Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHERYL A HULL

Allopathic & Osteopathic Physicians Dermatology

NPI
1124081849
CMS profile
142103
Location
ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$231.11

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $231.11 11

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHERYL A HULL

NPI 1124081849 · CMS profile ID 142103

Allopathic & Osteopathic Physicians / Dermatology

ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124081849?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124081849?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124081849?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124081849?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $231.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $14.7312/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753377775 CMS
GENZYME CORPORATION $16.0612/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744206425 CMS
AbbVie Inc. $12.5310/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890423 CMS
Galderma Laboratories, L.P. $12.5110/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726853687 CMS
Allergan, Inc. $14.7809/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723718299 CMS
AbbVie Inc. $11.6009/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721890419 CMS
Allergan, Inc. $12.6508/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723718297 CMS
Galderma Laboratories, L.P. $12.3108/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726853683 CMS
Galderma Laboratories, L.P. $12.7103/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726853681 CMS
Allergan, Inc. $21.9201/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723718295 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $89.3101/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737464623 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,430.05 27
PY2020 $231.11 11
PY2021 $627.01 26
PY2022 $517.89 25
PY2023 $1,474.67 21
PY2024 $880.69 32
PY2025 $676.63 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $380,038.55 259
PY2024 Principal investigator $408,860.46 382
PY2023 Principal investigator $228,849.11 170
PY2022 Recipient $321.00 1
PY2022 Principal investigator $248,165.36 66
PY2021 Recipient $2,700.00 2
PY2021 Principal investigator $244,500.15 37
PY2020 Recipient $643.47 2
PY2020 Principal investigator $251,307.20 46
PY2019 Recipient $4.75 1
PY2019 Principal investigator $990,287.65 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

93 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie, Inc. $1,567.80 12/30/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606259
Principal investigator 1 Bausch Health US, LLC $9,729.00 12/20/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684366893
Principal investigator 1 AbbVie, Inc. $669.40 12/19/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-999 No dispute reported 06/30/2026 647606255
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 12/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708445971
Principal investigator 1 AbbVie, Inc. $1,533.00 11/27/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606261
Principal investigator 1 Amgen Inc. $4,137.60 11/25/2019 Non-covered Recipient Entity
HULL DERMATOLOGY & AESTHETICS - NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study of the Efficacy and Safety of Apremilast CC-10004 in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp STYLE No dispute reported 06/30/2026 675786111
Principal investigator 1 Bausch Health US, LLC $16,045.00 11/25/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684366405
Principal investigator 1 AbbVie, Inc. $4,038.60 11/21/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-999 No dispute reported 06/30/2026 647606253
Principal investigator 1 Bausch Health US, LLC $14,496.00 11/18/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684366131
Principal investigator 1 AbbVie, Inc. $1,567.80 11/14/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606263
Principal investigator 1 PFIZER INC. $600.00 11/13/2019 Non-covered Recipient Entity
NW ARKANSAS CLINICAL TRIALS CTR PLLC
A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF06651600 AND PF06700841 IN SUBJECTS WITH MODERATE TO SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 671667019
Principal investigator 1 Bausch Health US, LLC $5,917.00 11/09/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIAL CENTER
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 684366053
Principal investigator 1 Incyte Corporation $3,285.90 11/06/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476623
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 11/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708445969
Principal investigator 1 AbbVie, Inc. $1,075.60 10/21/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-999 No dispute reported 06/30/2026 647606247
Principal investigator 1 AbbVie, Inc. $1,066.20 10/15/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606257
Principal investigator 1 Bausch Health US, LLC $1,797.00 10/09/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684365520
Principal investigator 1 Bausch Health US, LLC $8,290.00 10/09/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684365525
Principal investigator 1 AbbVie, Inc. $2,580.00 10/02/2019 Non-covered Recipient Entity
HULL DERMATOLOGY P.A.
P10-023 No dispute reported 06/30/2026 647606237
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 10/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708445967
Principal investigator 1 AbbVie, Inc. $2,452.80 09/26/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606251
Principal investigator 1 Bausch Health US, LLC $8,548.00 09/10/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684365161
Principal investigator 1 Incyte Corporation $30.40 09/10/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476615
Principal investigator 1 Incyte Corporation $28.65 09/10/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476617
Principal investigator 1 Incyte Corporation $23.40 09/10/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476619
Principal investigator 1 Incyte Corporation $23.40 09/10/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476621
Principal investigator 1 Incyte Corporation $2,937.60 09/04/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476609
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 09/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708445891
Principal investigator 1 Janssen Research & Development, LLC $1,884.60 08/29/2019 Non-covered Recipient Entity
Nw Arkansas Clnc Trials Ctr Pllc
A multicenter open registry of patients with psoriasis who are candidates for systematic therapy including biologics No dispute reported 06/30/2026 654254529
Principal investigator 1 AbbVie, Inc. $1,567.80 08/28/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606249
Principal investigator 1 Aclaris Therapeutics, Inc. $70.00 08/20/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700989791
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,100.00 08/20/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 704144191
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 08/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708445869
Principal investigator 1 Bausch Health US, LLC $3,884.00 07/29/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684364511
Principal investigator 1 AbbVie, Inc. $1,533.00 07/26/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606243
Principal investigator 1 AbbVie, Inc. $2,097.60 07/25/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606245
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $1.25 07/25/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 703550517
Principal investigator 1 Aclaris Therapeutics, Inc. $1,450.00 07/23/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700989249
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $359.30 07/09/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425919
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $4,272.00 07/02/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425915
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $250.00 07/02/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425917
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 07/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708446013
Principal investigator 1 Incyte Corporation $2,937.60 07/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476607
Principal investigator 1 Bausch Health US, LLC $6,398.00 06/28/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684364091
Principal investigator 1 AbbVie, Inc. $1,567.80 06/27/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606241
Principal investigator 1 Eli Lilly and Company $1,299.12 06/25/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 654292279
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $6.71 06/18/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 703550353
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 06/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708446031
Principal investigator 1 Bausch Health US, LLC $4,481.00 05/31/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684363803
Principal investigator 1 Bausch Health US, LLC $6,375.00 05/30/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684363707
Principal investigator 1 AbbVie, Inc. $1,066.20 05/29/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606239
Recipient Eli Lilly and Company $4.75 05/29/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 654281915
Principal investigator 1 Aclaris Therapeutics, Inc. $150.00 05/28/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700988645
Principal investigator 1 Janssen Research & Development, LLC $1,245.60 05/23/2019 Non-covered Recipient Entity
Nw Arkansas Clnc Trials Ctr Pllc
A multicenter open registry of patients with psoriasis who are candidates for systematic therapy including biologics No dispute reported 06/30/2026 654254527
Principal investigator 1 Celgene Corporation $500.00 05/09/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIAL
A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) (CC-10004-SPSO-001) No dispute reported 06/30/2026 675418165
Principal investigator 1 Aclaris Therapeutics, Inc. $2,000.00 05/07/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700988301
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 05/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708445917
Principal investigator 1 Aclaris Therapeutics, Inc. $775.00 04/25/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700988037
Principal investigator 1 Celgene Corporation $730.51 04/23/2019 Non-covered Recipient Entity
Hull Dermatology & Aesthetics - Northwest Arkansas Clinical Trials Center
A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) No dispute reported 06/30/2026 675417393
Principal investigator 1 Celgene Corporation $41,796.30 04/18/2019 Non-covered Recipient Entity
Hull Dermatology & Aesthetics - Northwest Arkansas Clinical Trials Center
A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) No dispute reported 06/30/2026 675417391
Principal investigator 1 Aclaris Therapeutics, Inc. $2,500.00 04/11/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700987897
Principal investigator 1 Incyte Corporation $23.40 04/08/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476601
Principal investigator 1 Incyte Corporation $19.10 04/08/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476603
Principal investigator 1 Incyte Corporation $23.40 04/08/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476605
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 04/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708446051
Principal investigator 1 AbbVie, Inc. $2,097.60 03/29/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606267
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $1,361.59 03/26/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 703550337
Principal investigator 1 Aclaris Therapeutics, Inc. $985.00 03/19/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700987711
Principal investigator 1 Incyte Corporation $1,395.00 03/08/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476595
Principal investigator 1 Aclaris Therapeutics, Inc. $1,205.00 03/05/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700987431
Principal investigator 1 Incyte Corporation $4,420.80 03/02/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476593
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 03/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708445935
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $702.00 03/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425953
Principal investigator 1 AbbVie, Inc. $1,567.80 02/28/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606265
Principal investigator 1 Janssen Research & Development, LLC $617.40 02/22/2019 Non-covered Recipient Entity
Nw Arkansas Clnc Trials Ctr Pllc
A multicenter open registry of patients with psoriasis who are candidates for systematic therapy including biologics No dispute reported 06/30/2026 654254531
Principal investigator 1 Bausch Health US, LLC $3,339.00 02/21/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684348745
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $108.73 02/19/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 703550067
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $248.96 02/15/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 703550074
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,191.50 02/15/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 640722511
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $65.00 02/12/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708446065
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $303.23 02/08/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 703550077
Principal investigator 1 Incyte Corporation $5,672.70 02/07/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476589
Principal investigator 1 Incyte Corporation $500.00 02/07/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476591
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,155.88 02/04/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 704733723
Principal investigator 1 Boehringer Ingelheim Canada Ltd.Ltee $132.50 02/01/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 708446079
Principal investigator 1 AbbVie, Inc. $1,533.00 01/28/2019 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
M15-997 No dispute reported 06/30/2026 647606269
Principal investigator 1 Incyte Corporation $61.84 01/28/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476571
Principal investigator 1 Aclaris Therapeutics, Inc. $195.00 01/22/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700986743
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,604.40 01/17/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CTR PLLC
Phase IIa study in patients with atopic dermatitis No dispute reported 06/30/2026 704143969
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $43,779.84 01/15/2019 Non-covered Recipient Entity
Dr Cheryl Hull
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 639760995
Principal investigator 1 Novartis Pharmaceuticals Corporation $701,247.84 01/07/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB IN SUBJECTS OF BODY WEIGHT 90 KG OR HIGHER WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS No dispute reported 06/30/2026 640722515
Principal investigator 1 Incyte Corporation $1,134.90 01/04/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 666476587
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $2,531.70 01/02/2019 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425939